184 related articles for article (PubMed ID: 36097219)
1. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF
Elez E; Ros J; Fernández J; Villacampa G; Moreno-Cárdenas AB; Arenillas C; Bernatowicz K; Comas R; Li S; Kodack DP; Fasani R; Garcia A; Gonzalo-Ruiz J; Piris-Gimenez A; Nuciforo P; Kerr G; Intini R; Montagna A; Germani MM; Randon G; Vivancos A; Smits R; Graus D; Perez-Lopez R; Cremolini C; Lonardi S; Pietrantonio F; Dienstmann R; Tabernero J; Toledo RA
Nat Med; 2022 Oct; 28(10):2162-2170. PubMed ID: 36097219
[TBL] [Abstract][Full Text] [Related]
2. BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes With Targeted Therapies in Real-World Cases of Colorectal Cancer.
Quintanilha JCF; Graf RP; Oxnard GR
Oncologist; 2023 Mar; 28(3):e171-e174. PubMed ID: 36779536
[TBL] [Abstract][Full Text] [Related]
3. Association of RNF43 Genetic Alterations With BRAF
Vogel A; Murugesan K; Kendre G; Quintanilha JCF; Ross JS; Brummer T; Saborowski A
JCO Precis Oncol; 2024 Feb; 8():e2300411. PubMed ID: 38394466
[TBL] [Abstract][Full Text] [Related]
4. RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer.
Matsumoto A; Shimada Y; Nakano M; Oyanagi H; Tajima Y; Nakano M; Kameyama H; Hirose Y; Ichikawa H; Nagahashi M; Nogami H; Maruyama S; Takii Y; Ling Y; Okuda S; Wakai T
Oncol Rep; 2020 Jun; 43(6):1853-1862. PubMed ID: 32236609
[TBL] [Abstract][Full Text] [Related]
5. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
6. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
Shinozaki E; Yoshino T; Yamazaki K; Muro K; Yamaguchi K; Nishina T; Yuki S; Shitara K; Bando H; Mimaki S; Nakai C; Matsushima K; Suzuki Y; Akagi K; Yamanaka T; Nomura S; Fujii S; Esumi H; Sugiyama M; Nishida N; Mizokami M; Koh Y; Abe Y; Ohtsu A; Tsuchihara K
Br J Cancer; 2017 Nov; 117(10):1450-1458. PubMed ID: 28972961
[TBL] [Abstract][Full Text] [Related]
8. The Evolving Treatment Landscape in
Tabernero J; Ros J; Élez E
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-10. PubMed ID: 35503983
[TBL] [Abstract][Full Text] [Related]
9. Predictive Impact of
Moretto R; Germani MM; Ros J; Daniel F; Ghelardi F; Vetere G; Giordano M; Toledo RA; Bergamo F; Randon G; Elez E; Lonardi S; Pietrantonio F; Vignali P; Rossini D; Matito J; Ugolini C; Fontanini G; Masi G; Cremolini C
JCO Precis Oncol; 2023 Sep; 7():e2300255. PubMed ID: 37797285
[TBL] [Abstract][Full Text] [Related]
10. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments.
Ros J; Matito J; Villacampa G; Comas R; Garcia A; Martini G; Baraibar I; Saoudi N; Salvà F; Martin Á; Antista M; Toledo R; Martinelli E; Pietrantonio F; Boccaccino A; Cremolini C; Dientsmann R; Tabernero J; Vivancos A; Elez E
Ann Oncol; 2023 Jun; 34(6):543-552. PubMed ID: 36921693
[TBL] [Abstract][Full Text] [Related]
11. Wild-type APC Is Associated with Poor Survival in Metastatic Microsatellite Stable Colorectal Cancer.
Wang C; Ouyang C; Cho M; Ji J; Sandhu J; Goel A; Kahn M; Fakih M
Oncologist; 2021 Mar; 26(3):208-214. PubMed ID: 33230914
[TBL] [Abstract][Full Text] [Related]
12. DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.
Innocenti F; Mu W; Qu X; Ou FS; Kabbarah O; Blanke CD; Venook AP; Lenz HJ; Rashid NU
J Clin Oncol; 2024 Feb; 42(4):399-409. PubMed ID: 37992266
[TBL] [Abstract][Full Text] [Related]
13. BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis.
Mao C; Liao RY; Qiu LX; Wang XW; Ding H; Chen Q
Mol Biol Rep; 2011 Apr; 38(4):2219-23. PubMed ID: 20857202
[TBL] [Abstract][Full Text] [Related]
14. RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis.
Bond CE; McKeone DM; Kalimutho M; Bettington ML; Pearson SA; Dumenil TD; Wockner LF; Burge M; Leggett BA; Whitehall VL
Oncotarget; 2016 Oct; 7(43):70589-70600. PubMed ID: 27661107
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer.
Seeber A; Battaglin F; Zimmer K; Kocher F; Baca Y; Xiu J; Spizzo G; Novotny-Diermayr V; Rieder D; Puccini A; Swensen J; Ellis M; Goldberg RM; Grothey A; Shields AF; Marshall JL; Weinberg BA; Sackstein PE; Lim KH; Tan GS; Nabhan C; Korn WM; Amann A; Trajanoski Z; Berger MD; Lou E; Wolf D; Lenz HJ
Clin Cancer Res; 2022 May; 28(9):1863-1870. PubMed ID: 35254413
[TBL] [Abstract][Full Text] [Related]
16. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer.
Seppälä TT; Böhm JP; Friman M; Lahtinen L; Väyrynen VM; Liipo TK; Ristimäki AP; Kairaluoma MV; Kellokumpu IH; Kuopio TH; Mecklin JP
Br J Cancer; 2015 Jun; 112(12):1966-75. PubMed ID: 25973534
[TBL] [Abstract][Full Text] [Related]
17. Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies.
Cui D; Cao D; Yang Y; Qiu M; Huang Y; Yi C
Mol Biol Rep; 2014 Mar; 41(3):1291-8. PubMed ID: 24390240
[TBL] [Abstract][Full Text] [Related]
18. Treatment of patients with BRAF
Germani MM; Vetere G; Santamaria F; Intini R; Ghelardi F; Bensi M; Boccaccino A; Minelli A; Carullo M; Ciracì P; Passardi A; Santucci S; Giampieri R; Persano M; Fenocchio E; Puccini A; Lonardi S; Pietrantonio F; Salvatore L; Cremolini C
ESMO Open; 2024 Apr; 9(4):102996. PubMed ID: 38613911
[TBL] [Abstract][Full Text] [Related]
19. Exome sequencing revealed comparable frequencies of RNF43 and BRAF mutations in Middle Eastern colorectal cancer.
Siraj AK; Bu R; Masoodi T; Parvathareddy SK; Iqbal K; Al-Haqawi W; Al-Dossari H; Azam S; Qadri Z; Annaiyappanaidu P; Al-Dayel F; Al-Kuraya KS
Sci Rep; 2022 Jul; 12(1):13098. PubMed ID: 35907983
[TBL] [Abstract][Full Text] [Related]
20. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
J Gastrointest Cancer; 2019 Jun; 50(2):269-275. PubMed ID: 29388061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
